USD 946.31 million growth expected in Contrast Media Market between 2022-2027|Rise in healthcare spending drives market growth- Technavio
NEW YORK, Aug. 30, 2023 /PRNewswire/ -- The contrast media market is anticipated to grow by USD 946.31 million from 2022 to 2027, accelerating at a CAGR of 3.36%. Rising global healthcare spending and increased medical investments in countries like the US, India, and Brazil, are primary drivers for the growth of the contrast media market. The high expenditure aims to support healthcare infrastructure, meet patient demands, and provide advanced medical care, consequently boosting the adoption of diagnostic imaging with contrast media. This report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. Download the sample report now
Contrast Media Market 2023-2027: Segmentation
- Modality
- X-ray/CT
- MRI
- Ultrasound
- Application
- Neurological Disorders
- Cardiovascular Disorders
- Cancer
- Gastrointestinal Disorders
- Others
- Geography
- North America
- Europe
- APAC
- South America
- Middle East And Africa
Receive our market sample report now to gain access to detailed analysis on the contrast media market. Get the sample report now
Contrast Media Market 2023-2027: Vendor Analysis and Scope
To help businesses improve their market position, the contrast media market provides a detailed analysis of major companies operating in the market.
Beijing Beilu Pharmaceutical Co. Ltd.: The company provides a range of contrast media, including Gadopentetate Dimeglumine Injection. Additionally, the company is actively involved in the advancement of contrast media research and development, as well as the creation of traditional Chinese medicine for anti-anxiety purposes and pharmaceuticals targeting anti-diabetic treatments.
Some of the other companies include:
- Bayer AG
- Beijing Beilu Pharmaceutical Co. Ltd.
- Blue Jet Healthcare Ltd.
- Bracco Spa
- Covis Pharma GmbH
- GE Healthcare Technologies Inc.
- Guerbet
- iMAX Diagnostic Imaging Ltd
- Interpharma Praha as
- JB Chemicals and Pharmaceuticals Ltd.
- Jodas Expoim Pvt. Ltd.
- Lantheus Holdings Inc.
- Livealth Biopharma Pvt. Ltd.
- M.Biotech Ltd.
- Nano Therapeutics Pvt. Ltd.
- Novalek Pharmaceuticals Pvt Ltd.
- SANOCHEMIA Pharmazeutika GmbH
- Spago Nanomedical AB
- Taejoon Pharm Co. Ltd.
- Unijules Life Sciences Ltd
Related Reports:
Contrast Injectors Market: The contrast injectors market share is expected to increase by USD 578.41 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5%. This report extensively covers market segmentation by product (consumables and contrast injectors) and geography (North America, Europe, Asia, and ROW).
High Pressure Contrast Media Injectors Market: The high pressure contrast media injectors market share should rise by USD 113.21 million from 2022 to 2026 at a CAGR of 12.32%. This report extensively covers market segmentation by end-user (hospitals, diagnostics centers, and ambulatory surgical centers) and geography (North America, Europe, Asia, and ROW).
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article